Showing results (191-200 of 276) with videos related to

Sort By:
Pageof 28
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancerIgnace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2024
Diagnostic Accuracy of <sup>68</sup>Ga-FAPI Versus <sup>18</sup>F-FDG PET in Patients with Various MalignanciesNader Hirmas, Rainer Hamacher, Miriam Sraieb, et al.
Journal of Medical Genetics|December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i>: results of the observational AGO-TR1 study (NCT02222883)Jan Hauke, Philipp Harter, Corinna Ernst, et al.
International Journal of Cancer|August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancerIsabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 21, 2015
Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian StudyJae-Weon Kim, Sven Mahner, Ling-Ying Wu, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trialLiselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2024
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancerRomain Boidot, Michael G B Blum, Marie-Pierre Wissler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian CancerFlorian Heitz, Stefan Kommoss, Roshan Tourani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 ConsortiumNicole Concin, Ioana Braicu, Pierre Combe, et al.
Pageof 28